600079 ST人福
已收盘 02-06 15:00:00
资讯
新帖
简况
每周股票复盘：ST人福（600079）参与设立私募基金完成备案
证券之星 · 02-01
每周股票复盘：ST人福（600079）参与设立私募基金完成备案
ST人福（600079）披露参与设立私募基金暨关联交易进展公告，1月30日股价上涨1.1%
证券之星 · 01-30
ST人福（600079）披露参与设立私募基金暨关联交易进展公告，1月30日股价上涨1.1%
每周股票复盘：ST人福（600079）子公司ICU镇痛药申请获受理
证券之星 · 01-18
每周股票复盘：ST人福（600079）子公司ICU镇痛药申请获受理
ST人福(600079.SH)：HW221043片获得药物临床试验批准通知书
智通财经 · 01-05
ST人福(600079.SH)：HW221043片获得药物临床试验批准通知书
流感疫情持续，防控系统工程再受考验
证券之星 · 2025-12-31
流感疫情持续，防控系统工程再受考验
ST人福：副总经理郑承刚、张红杰等人因未及时披露公司重大事件等违规行为被上海证券交易所公开谴责
证券之星 · 2025-12-30
ST人福：副总经理郑承刚、张红杰等人因未及时披露公司重大事件等违规行为被上海证券交易所公开谴责
ST人福遭中国证监会警示并处罚 涉信披违规
美股速递 · 2025-12-29
ST人福遭中国证监会警示并处罚 涉信披违规
ST人福（600079）披露参与设立私募基金暨关联交易进展公告，12月24日股价下跌2.06%
证券之星 · 2025-12-24
ST人福（600079）披露参与设立私募基金暨关联交易进展公告，12月24日股价下跌2.06%
ST人福(600079.SH)：招商生科累计增持2%股份
中金财经 · 2025-12-22
ST人福(600079.SH)：招商生科累计增持2%股份
中粮资本：ST人福风险不传导至公司资产
证券之星 · 2025-12-19
中粮资本：ST人福风险不传导至公司资产
ST人福(600079.SH)：HW252001片获得药物临床试验批准通知书
智通财经 · 2025-12-19
ST人福(600079.SH)：HW252001片获得药物临床试验批准通知书
ST人福涨5.03%，太平洋一个月前给出“买入”评级
证券之星 · 2025-12-19
ST人福涨5.03%，太平洋一个月前给出“买入”评级
从麻醉一哥到ST人福：一场资本游戏后的生死蜕变
新浪证券 · 2025-12-17
从麻醉一哥到ST人福：一场资本游戏后的生死蜕变
因巨额资金违规占用等多项违规被罚，人福医药将“戴帽”
新京报 · 2025-12-15
因巨额资金违规占用等多项违规被罚，人福医药将“戴帽”
人福医药宣布将于12月15日暂停交易以实施其他风险警示，交易将于12月16日恢复
美股速递 · 2025-12-12
人福医药宣布将于12月15日暂停交易以实施其他风险警示，交易将于12月16日恢复
人福医药(600079.SH)：咪达唑仑注射液获德国上市许可批准
智通财经 · 2025-12-11
人福医药(600079.SH)：咪达唑仑注射液获德国上市许可批准
人福医药（600079）披露子公司撤回药品注册申请，12月03日股价下跌3.33%
证券之星 · 2025-12-03
人福医药（600079）披露子公司撤回药品注册申请，12月03日股价下跌3.33%
人福医药最新公告：子公司撤回重组质粒-肝细胞生长因子注射液药品注册申请
证券之星 · 2025-12-02
人福医药最新公告：子公司撤回重组质粒-肝细胞生长因子注射液药品注册申请
人福医药最新公告：子公司HWS117注射液获得临床试验批准通知书
证券之星 · 2025-11-28
人福医药最新公告：子公司HWS117注射液获得临床试验批准通知书
人福医药(600079.SH)：二甲磺酸利右苯丙胺胶囊上市许可申请获受理
智通财经 · 2025-11-21
人福医药(600079.SH)：二甲磺酸利右苯丙胺胶囊上市许可申请获受理
加载更多
公司概况
公司名称：
人福医药集团股份公司
所属行业：
医药制造业
上市日期：
1997-06-06
主营业务：
人福医药集团股份公司的主营业务是药品的研发、生产和销售。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、祖卡木颗粒、复方木尼孜其颗粒、注射用尿激酶、硫酸新霉素原料药、黄体酮原料药。
发行价格：
5.22
{"stockData":{"symbol":"600079","market":"SH","secType":"STK","nameCN":"ST人福","latestPrice":19.28,"timestamp":1770361201000,"preClose":19.23,"halted":0,"volume":18914799,"delay":0,"changeRate":0.0026,"floatShares":1543000000,"shares":1632000000,"eps":0.8753,"marketStatus":"已收盘","change":0.05,"latestTime":"02-06 15:00:00","open":19.16,"high":19.41,"low":19.06,"amount":364000000,"amplitude":0.0182,"askPrice":19.28,"askSize":803,"bidPrice":19.27,"bidSize":224,"shortable":0,"etf":0,"ttmEps":0.8753,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":19.23,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":20.19,"lowLimit":18.27,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":1632225965,"isCdr":false,"pbRate":1.66,"roa":"--","peRate":22.026734,"roe":"9.2%","epsLYR":0.82,"committee":-0.099352,"marketValue":31469000000,"turnoverRate":0.0123,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-02-09。","floatMarketCap":29752000000},"requestUrl":"/m/hq/s/600079","defaultTab":"news","newsList":[{"id":"2608807278","title":"每周股票复盘：ST人福（600079）参与设立私募基金完成备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2608807278","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608807278?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:58","pubTimestamp":1769882291,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，ST人福报收于18.38元，较上周的18.24元上涨0.77%。本周，ST人福1月30日盘中最高价报18.88元。ST人福当前最新总市值300.0亿元，在化学制药板块市值排名14/150，在两市A股市值排名707/5184。本周关注点公司公告汇总：人福医药参与设立的创业投资基金完成备案，认缴出资7,500万元。公司已累计对外投资多支私募基金，总金额达6.175亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0028","BK0012","600079","BK0096","BK0239","BK0188","BK0070"],"gpt_icon":0},{"id":"2607504907","title":"ST人福（600079）披露参与设立私募基金暨关联交易进展公告，1月30日股价上涨1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607504907","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607504907?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:22","pubTimestamp":1769782941,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，ST人福报收于18.38元，较前一交易日上涨1.1%，最新总市值为300亿元。该股当日开盘18.17元，最高18.88元，最低18.14元，成交额达5.03亿元，换手率为1.76%。近日，ST人福发布《关于参与设立私募基金暨关联交易的进展公告》。本次投资资金来源为公司自有资金，不影响公司主营业务正常运行，不改变公司合并报表范围。公司已累计对外投资多支私募基金，总金额达6.175亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","600079","BK0012","BK0070","BK0096","BK0188","BK0239","BK0028"],"gpt_icon":0},{"id":"2604192368","title":"每周股票复盘：ST人福（600079）子公司ICU镇痛药申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2604192368","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604192368?lang=zh_cn&edition=full","pubTime":"2026-01-18 02:42","pubTimestamp":1768675328,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，ST人福报收于18.43元，较上周的18.2元上涨1.26%。本周，ST人福1月13日盘中最高价报18.85元。ST人福当前最新总市值300.82亿元，在化学制药板块市值排名15/150，在两市A股市值排名698/5183。本周关注点公司公告汇总：子公司盐酸纳布啡注射液新增ICU镇痛适应症上市申请获受理，全球尚无同类产品获批该适应症。该产品此前已获批用于复合麻醉诱导和术后镇痛。截至目前，该项目累计研发投入约1600万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0096","BK0239","BK0185","BK0012","BK0188","600079","BK0070"],"gpt_icon":0},{"id":"2601001793","title":"ST人福(600079.SH)：HW221043片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2601001793","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601001793?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:52","pubTimestamp":1767603150,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST人福(600079.SH)发布公告，公司全资子公司湖北生物医药产业技术研究院有限公司(简称“研究院有限公司”)近日收到国家药品监督管理局核准签发的HW221043片的《药物临床试验批准通知书》。HW221043片拟用于晚期实体瘤的治疗，是由公司自主研发的新分子实体化合物，目前国内外暂无同类药物获批上市。截至目前，HW221043片累计研发投入约为2,400万元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ST人福(600079.SH)：HW221043片获得药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0012","BK0185","BK0096","BK0070","600079","BK0188","BK0239"],"gpt_icon":0},{"id":"2595127727","title":"流感疫情持续，防控系统工程再受考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2595127727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595127727?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:18","pubTimestamp":1767172695,"startTime":"0","endTime":"0","summary":"2025年末，全国流感疫情持续处于高流行水平。产业链协同响应，构建多层次供应保障流感防控是一项系统工程，需要疫苗预防、快速诊断、药物治疗等多个环节的有效衔接。本轮疫情中，上市药企正通过全产业链布局，搭建从源头预防到终端治疗的健康保障网络。中成药在本轮疫情中表现活跃。公司表示，金振口服液四季度市场需求回暖，正加紧排产满足市场需要。随着该产品儿童流感新适应症的获批，其在儿科领域的应用场景进一步拓宽。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025123100030908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0070","000999","BK0197","300937","BK0284","300244","002728","BK0012","BK0114","600079","BK0010","BK0196","603858","BK0175","600566","002317","002603","002393","BK0186","000623","BK0074","600557","BK0046","BK0188","BK0201","BK0146","BK0060","BK0086","SG9999001069.SGD","301207","BK0097","688276","BK0183","BK0077","BK0187","BK0042","BK0164","BK0028","603882","BK0185","BK0236","BK0239","BK0250","BK0096"],"gpt_icon":0},{"id":"2595879977","title":"ST人福：副总经理郑承刚、张红杰等人因未及时披露公司重大事件等违规行为被上海证券交易所公开谴责","url":"https://stock-news.laohu8.com/highlight/detail?id=2595879977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595879977?lang=zh_cn&edition=full","pubTime":"2025-12-30 19:00","pubTimestamp":1767092448,"startTime":"0","endTime":"0","summary":"证券之星消息，12月29日ST人福公开信息显示，副总经理郑承刚、张红杰、夏渊因未及时披露公司重大事件,涉嫌违反证券法律法规,未依法履行其他职责被上海证券交易所公开谴责。上述关联交易是在当代集团要求和安排下进行。2024年7月27日,人福医药披露《关于子公司购买物业资产暨关联交易的公告》,将珂美立德披露为关联人。珂美立德是人福医药案涉期间的关联人,控股股东当代集团未按规定及时向上市公司报送关联人关系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000035240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0070","BK0012","BK0185","600079","BK0188","BK0096"],"gpt_icon":0},{"id":"1160609677","title":"ST人福遭中国证监会警示并处罚 涉信披违规","url":"https://stock-news.laohu8.com/highlight/detail?id=1160609677","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160609677?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:59","pubTimestamp":1767002350,"startTime":"0","endTime":"0","summary":"ST人福（600079）公告称，公司因涉嫌违反信息披露相关规定，被中国证券监督管理委员会采取警示及罚款的监管措施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0012","600079","BK0188","BK0185","BK0239","BK0070","BK0096"],"gpt_icon":0},{"id":"2593708484","title":"ST人福（600079）披露参与设立私募基金暨关联交易进展公告，12月24日股价下跌2.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593708484","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593708484?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:06","pubTimestamp":1766585169,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，ST人福报收于19.05元，较前一交易日下跌2.06%，最新总市值为310.94亿元。该股当日开盘19.27元，最高19.3元，最低19.0元，成交额达5.64亿元，换手率为1.92%。公司近日发布公告称，人福医药集团股份公司参与投资设立武汉睿成新药科技成果转化创业投资基金中心，认缴出资7,500万元，首期出资额2.5亿元已全部缴付到位。本次投资资金来源为公司自有资金，不影响公司正常经营，不改变合并报表范围。公司已累计对外投资私募基金合计61,750万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400040106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0070","600079","BK0028","BK0096","BK0188","BK0185"],"gpt_icon":0},{"id":"2593489454","title":"ST人福(600079.SH)：招商生科累计增持2%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2593489454","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593489454?lang=zh_cn&edition=full","pubTime":"2025-12-22 18:47","pubTimestamp":1766400422,"startTime":"0","endTime":"0","summary":"格隆汇12月22日丨ST人福(600079.SH)公布，公司于2025年12月22日收到招商生科《关于增持人福医药集团股份公司股份实施结果的告知函》，2025年7月17日至2025年12月22日，招商生科通过上海证券交易所交易系统以集中竞价交易方式累计增持公司股份32,644,497股，占公司总股本的2%，增持金额合计为65,417.15万元(不含交易费用)，本次增持计划实施完毕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251222/31881799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","BK0012","600079","BK0188","BK0185","BK0239","BK0070","BK0096"],"gpt_icon":0},{"id":"2592516420","title":"中粮资本：ST人福风险不传导至公司资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2592516420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592516420?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:52","pubTimestamp":1766148725,"startTime":"0","endTime":"0","summary":"ST人福股票由中粮信托设立的破产重整服务信托持有，中粮信托依据信托合同约定提供受托服务，ST人福股票为该破产重整服务信托的信托财产，独立于中粮信托固有财产，也独立于中粮信托管理的其他产品的信托财产，ST人福自身的风险不会直接传导至中粮资本或中粮信托的其他资产与业务。公司将持续密切关注ST人福的整改进展、经营状况、财务状况。关于ST人福的未来发展，请以对方公告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900036458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0272","BK0239","002423","BK0012","600079","BK0188","BK0185","BK0096","BK0070","BK0010"],"gpt_icon":0},{"id":"2592975159","title":"ST人福(600079.SH)：HW252001片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2592975159","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592975159?lang=zh_cn&edition=full","pubTime":"2025-12-19 15:46","pubTimestamp":1766130403,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST人福(600079.SH)发布公告，公司全资子公司湖北生物医药产业技术研究院有限公司近日收到国家药品监督管理局核准签发的HW252001片的《药物临床试验批准通知书》，同意开展用于特发性肺纤维化适应症的临床试验。HW252001片拟用于特发性肺纤维化的治疗，是一款口服的小分子新药。截至目前，该项目累计研发投入约为2,000万元人民币。特发性肺纤维化(IPF)是一种致病原因不明的间质性肺疾病，具有组织病理学/影像学特征，表现为肺功能进行性下降，出现急性加重和呼吸衰竭，预后较差。IPF的主要治疗方式为抗纤维化药物治疗，用于延缓肺功能下降和疾病进展，目前尚无根治性治疗手段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0185","BK0239","600079","BK0188","BK0096","BK0012","BK0028"],"gpt_icon":0},{"id":"2592156720","title":"ST人福涨5.03%，太平洋一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2592156720","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592156720?lang=zh_cn&edition=full","pubTime":"2025-12-19 15:31","pubTimestamp":1766129488,"startTime":"0","endTime":"0","summary":"今日ST人福（600079）涨5.03%，收盘报19.22元。2025年11月5日，太平洋研究员谭紫媚,张懿发布了对人福医药的研报《人福医药：招商局赋能利好发展，多产品获批贡献增量》，该研报对人福医药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为33.02%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为开源证券的蔡明子。ST人福（600079）个股概况：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900017611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","600079"],"gpt_icon":0},{"id":"2592961096","title":"从麻醉一哥到ST人福：一场资本游戏后的生死蜕变","url":"https://stock-news.laohu8.com/highlight/detail?id=2592961096","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592961096?lang=zh_cn&edition=full","pubTime":"2025-12-17 15:07","pubTimestamp":1765955220,"startTime":"0","endTime":"0","summary":" 曾被誉为“麻醉一哥”的人福医药，在2025年岁末迎来一记重击。因年报财务数据虚假记载，公司收到湖北证监局的《行政处罚事先告知书》，股票自12月15日起停牌，复牌后简称变更为“ST人福（维权）”。其背后，是一场由大股东当代集团主导的资本游戏逐渐失控的故事。 ST帽子既是一次警醒，也可能成为重生的起点。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-12-17/doc-inhcavhm7558747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0070","BK0185","BK0239","600079","BK0188","BK0096","BK0012","BK0028"],"gpt_icon":0},{"id":"2591464330","title":"因巨额资金违规占用等多项违规被罚，人福医药将“戴帽”","url":"https://stock-news.laohu8.com/highlight/detail?id=2591464330","media":"新京报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591464330?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:24","pubTimestamp":1765797840,"startTime":"0","endTime":"0","summary":"《行政处罚事先告知书》显示，人福医药自2020年至2022年期间存在多项违法事实。除资金占用问题外，人福医药定期报告还存在虚假记载。基于以上违法事实，湖北证监局决定，对人福医药原控股股东当代集团处以900万元的罚款，对人福医药给予警告，并处以850万元的罚款。2025年，招商局集团通过司法重整正式入主人福医药。在企业治理方面，招商局入主后，人福医药内控与合规体系迅速向央企标准靠拢。","market":"sh","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2025/12/wangl88202512151850162832788.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2025/12/wangl88202512151850162832788.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1765797848168289.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1765797848168289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0188","BK0096","BK0012","BK0185","BK0028","BK0239","BK0070","600079"],"gpt_icon":0},{"id":"1144440220","title":"人福医药宣布将于12月15日暂停交易以实施其他风险警示，交易将于12月16日恢复","url":"https://stock-news.laohu8.com/highlight/detail?id=1144440220","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144440220?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:34","pubTimestamp":1765535666,"startTime":"0","endTime":"0","summary":"人福医药宣布将于12月15日暂停其股票交易，以实施其他风险警示，预计交易将于12月16日恢复。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0070","BK0239","BK0185","BK0012","600079","BK0028","BK0188","BK0096"],"gpt_icon":0},{"id":"2590593405","title":"人福医药(600079.SH)：咪达唑仑注射液获德国上市许可批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590593405","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590593405?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:15","pubTimestamp":1765440941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，人福医药(600079.SH)公告，公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”)收到德国联邦药品和医疗器械管理局(BfArM)核准签发的咪达唑仑注射液的上市许可批准信。公告显示咪达唑仑注射液获得德国联邦药品和医疗器械管理局(BfArM)的上市许可，被批准的适应症包括：1)在诊断或治疗性操作前后及过程中进行清醒镇静(无论是否联合局部麻醉);2)成人麻醉诱导前的术前用药、麻醉诱导、以及与其他麻醉剂作为镇静药物联合使用;儿童麻醉诱导前的术前用药;3)重症监护病房(ICU)中的镇静。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0239","BK0185","FDAXmain","FDXMmain","BK0012","FDXSmain","600079","BK0028","BK0188","BK0096"],"gpt_icon":0},{"id":"2588011992","title":"人福医药（600079）披露子公司撤回药品注册申请，12月03日股价下跌3.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011992","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588011992?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:04","pubTimestamp":1764752656,"startTime":"0","endTime":"0","summary":"截至2025年12月3日收盘，人福医药报收于18.57元，较前一交易日下跌3.33%，最新总市值为303.1亿元。公司于近日发布公告称，其控股子公司武汉光谷人福生物医药有限公司收到国家药品监督管理局签发的《药品注册申请终止通知书》，同意撤回重组质粒-肝细胞生长因子注射液的注册申请。截至目前，该项目累计研发投入约1.6亿元，收购日可辨认资产分摊金额为2.38亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300025645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0096","BK0239","BK0185","BK0012","BK0188","600079","BK0070"],"gpt_icon":0},{"id":"2588097034","title":"人福医药最新公告：子公司撤回重组质粒-肝细胞生长因子注射液药品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2588097034","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588097034?lang=zh_cn&edition=full","pubTime":"2025-12-02 18:49","pubTimestamp":1764672572,"startTime":"0","endTime":"0","summary":"人福医药公告称，公司控股子公司光谷人福收到国家药品监督管理局签发的《药品注册申请终止通知书》，同意其撤回重组质粒-肝细胞生长因子注射液的注册申请。光谷人福于2024年12月递交上市注册申请，截至目前累计研发投入约为1.6亿元。公司决定主动撤回本次申请，将根据监管要求和技术要求完善研究资料后重新申报。预计该事项不会对公司当期业绩造成重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200029746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","BK0239","BK0028","BK0096","600079","BK0185","BK0012"],"gpt_icon":0},{"id":"2586178565","title":"人福医药最新公告：子公司HWS117注射液获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586178565","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586178565?lang=zh_cn&edition=full","pubTime":"2025-11-28 18:20","pubTimestamp":1764325223,"startTime":"0","endTime":"0","summary":"人福医药(600079.SH)公告称，全资子公司湖北生物医药产业技术研究院有限公司近日收到国家药品监督管理局核准签发的HWS117注射液的《药物临床试验批准通知书》。HWS117注射液为一款新型长效FSH药物，拟通过延长FSH在体内的半衰期，满足减少注射频率、提高治疗依从性的临床需求。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800027686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0096","BK0188","BK0070","BK0028","BK0185","600079"],"gpt_icon":0},{"id":"2585419708","title":"人福医药(600079.SH)：二甲磺酸利右苯丙胺胶囊上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2585419708","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585419708?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:38","pubTimestamp":1763710735,"startTime":"0","endTime":"0","summary":"智通财经APP讯，人福医药 发布公告，公司控股子公司宜昌人福药业有限责任公司近日收到国家药品监督管理局核准签发的二甲磺酸利右苯丙胺胶囊的药品注册上市许可申请《受理通知书》。据悉，二甲磺酸利右苯丙胺胶囊原研最早于美国获批上市，用于治疗成人和6岁及以上儿科患者的注意缺陷多动障碍，以及成人中度至重度暴食症。根据国家药品监督管理局官网显示，国内目前暂无二甲磺酸利右苯丙胺胶囊上市，也无相关产品获批进口。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0012","BK0070","600079","BK0028","BK0096","BK0188","BK0185"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770498667064,"stockEarnings":[{"period":"1week","weight":0.049},{"period":"1month","weight":0.0478},{"period":"3month","weight":-0.0577},{"period":"6month","weight":-0.0907},{"period":"1year","weight":-0.0708},{"period":"ytd","weight":0.0646}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"人福医药集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"69442人(较上一季度增加38.71%)","perCapita":"22222股","listingDate":"1997-06-06","address":"湖北省武汉市洪山区东湖高新区高新大道666号","registeredCapital":"163222万元","survey":" 人福医药集团股份公司的主营业务是药品的研发、生产和销售。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、祖卡木颗粒、复方木尼孜其颗粒、注射用尿激酶、硫酸新霉素原料药、黄体酮原料药。","listedPrice":5.22},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST人福,600079,ST人福股票,ST人福股票老虎,ST人福股票老虎国际,ST人福行情,ST人福股票行情,ST人福股价,ST人福股市,ST人福股票价格,ST人福股票交易,ST人福股票购买,ST人福股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}